Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 377

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

Open access
Brentjens, Renier, Yeh, Raymond, Bernal, Yvette, Riviere, Isabelle, Sadelain, Michel·2010·Molecular Therapy

Abstract

To the editor:Most patients with B-cell malignancies will die from their disease or are incurable. For this reason, innovative therapeutic approaches are direly needed. Patient T cells may be genetically modified to target antigens expressed on tumor cells through the expression of chimeric antigen receptors (CARs), which are antigen receptors designed to recognize cell surface antigens in a human leukocyte antigen–independent manner.1Sadelain M Rivière I Brentjens R Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer. 2003; 3: 35-45Crossref PubMed Scopus (396) Google Scholar CD19, which is expressed on most B-cell malignancies—including most non-Hodgkin's lymphomas, acute lymphoblastic leukemias, and chronic lymphocytic leukemias (CLLs)—is an attractive antigen for this approach.2Brentjens RJ Latouche JB Santos E Marti F Gong MC Lyddane C et al.Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.Nat Med. 2003; 9: 279-286Crossref PubMed Scopus (503) Google Scholar It is present on normal B-lineage cells from the early pre–B-cell stage until plasma cell differentiation. In a model of CD19+ acute lymphoblastic leukemia, we found that that a CAR termed 19-28z, which comprises the CD28 cytoplasmic domain in addition to that of the CD3 ζ-chain,3Maher J Brentjens R Gunset G Rivière I Sadelain M Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.Nat Biotechnol. 2002; 20: 70-75Crossref PubMed Scopus (677) Google Scholar induced better responses than a ζ-chain-based receptor.4Brentjens RJ Santos E Nikhamin Y Yeh R Matsushita M La Perle K et al.Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.Clin Cancer Res. 2007; 13: 5426-5435Crossref PubMed Scopus (335) Google Scholar In preclinical in vitro studies, we demonstrated that human T cells that express CD19-specific CARs efficiently lyse human CD19+ tumor cell lines and that CLL patient–derived T cells effectively lyse autologous tumor cells.2Brentjens RJ Latouche JB Santos E Marti F Gong MC Lyddane C et al.Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.Nat Med. 2003; 9: 279-286Crossref PubMed Scopus (503) Google Scholar,4Brentjens RJ Santos E Nikhamin Y Yeh R Matsushita M La Perle K et al.Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.Clin Cancer Res. 2007; 13: 5426-5435Crossref PubMed Scopus (335) Google Scholar These results, and others,5Sadelain M Brentjens R Rivière I The promise and potential pitfalls of chimeric antigen receptors.Curr Opin Immunol. 2009; 21: 215-223Crossref PubMed Scopus (359) Google Scholar supported a phase I clinical trial treating refractory CLL patients with autologous T cells modified by retroviral gene transfer of the 19-28z CAR.We have thus far enrolled six patients in this clinical trial. The cohort of subjects treated with modified T cells alone at the first dose level of T cells tolerated therapy well without dose-limiting toxicities. However, the first subject (subject 4) enrolled in the second cohort of patients, in whom cyclophosphamide lymphodepleting chemotherapy was administered before infusion of the same T-cell dose, developed a syndrome of hypotension, dyspnea, and renal failure following T-cell infusion. Subject 4 died 4 days after administration of cyclophosphamide and modified T cells. Herein we describe the chronology of his treatment and report the findings of an extensive postmortem analysis.Clinical trial designSubject 4 was treated in a phase I clinical trial (IRB no. 06-138, NIH-RAC no. 0507-721, NCT00466531) designed to assess the safety of infusing autologous T cells modified to express the CD19-targeted CAR 19-28z in subjects with relapsed or purine analog–refractory CLL. For 2–3 days following T-cell infusion, the subjects are closely monitored for tumor lysis and unforeseen adverse events. If stable, subjects are discharged and subsequently closely followed in the outpatient clinic setting.This phase I clinical trial has a three-step design (Table 1). In the first step, subjects are treated with dose level 1 of modified T cells (1.2–3.0 × 107 CAR+ T cells/kg) without prior lymphodepleting chemotherapy. The subject of the current report was enrolled in cohort 1 of step 2 and treated with 1.5 g/m2 of cyclophosphamide followed 2 days later by infusion of modified T cells at dose level 1. The enrollment thus far is summarized in Table 1.Table 1Cyclophosphamide and T-cell doses in IRB protocol no. 06-138StepCyclophosphamideCAR + T-cell doseNo. of enrolled subjects101.2-3.0 × 107/kg321.5 g/m21.2-3.0 × 107/kg13.0 g/m21.2-3.0 × 107/kg03MTD0.4-1.0 × 108/kg0−11.5 g/m24.0-10 × 106/kg2CAR, chimeric antigen receptor; MTD, maximum-tolerated dose. Open table in a new tab Case reportSubject 4 was a 69-year-old man with refractory CLL

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2010.31

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 377

Metadata

Authors
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2010-04
Volume
18
Issue
4
Pages
666-668
ISSN
1525-0016 (ISSN-L)
OpenAlex
W1971746066
Cited by
377
References
6
FWCI
20.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.